Caverject

See also: Generic Caverject Impulse

Caverject is a brand name of alprostadil, approved by the FDA in the following formulation(s):

CAVERJECT (alprostadil - injectable; injection)

• 
  Manufacturer: PHARMACIA AND UPJOHN
  
  Approval date: July 6, 1995
  
  Strength(s): 0.01MG/VIAL ^[AP], 0.02MG/VIAL ^[RLD][AP]


• 
  Manufacturer: PHARMACIA AND UPJOHN
  
  Approval date: June 27, 1996
  
  Strength(s): 0.005MG/VIAL
  


• 
  Manufacturer: PHARMACIA AND UPJOHN
  
  Approval date: May 19, 1997
  
  Strength(s): 0.04MG/VIAL ^[RLD][AP]

Has a generic version of Caverject been approved?

A generic version of Caverject has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Caverject and have been approved by the FDA:

EDEX (alprostadil injectable; injection)

• 
  Manufacturer: SCHWARZ PHARMA
  
  Approval date: June 12, 1997
  
  Strength(s): 0.01MG/VIAL ^[AP], 0.02MG/VIAL ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Caverject. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Stabilized prostaglandin E1
  Patent 5,741,523
  Issued: April 21, 1998
  Inventor(s): Teagarden; Dirk L. & Petre; William J. & Gold; Paul M.
  Assignee(s): Pharmacia & Upjohn Company
  A stable and lyophilized formulation of prostaglandin E-1 made by the process comprising a) dissolving PGE-1 in a solution of lactose and tertiary butyl alcohol wherein said tertiary butyl alcohol is present in an amount of from about 15% to about 33% volume/volume and the ratio of said lactose to PGE-1 is from about 40,000 to 1 to about 10,000 to 1 weight/weight whereby a formulation of PGE-1dispersed in lactose is formed; b) adjusting and maintaining the pH of said formulation from about 3.5 to about 6 with an organic acid buffer; c) freezing said formulation to about -50.degree. C.; and d) drying said formulation to obtain a moisture content of less than 1% by dry weight and a tertiary butyl alcohol content of less than 3% by dry weight. Preferably, step c) includes after freezing said formulation to about -50.degree. C., warming to about -25.degree. C. for about 2 hours then refreezing to about 50.degree. C. Preferably, the prostaglandin is in an amount of about 25 to 100 ppm in lactose and the pH is maintained at about 4 to 5.
  
  Patent expiration dates:
  
  
  • April 21, 2015
    
  
  

See also...

• Caverject Consumer Information (Wolters Kluwer)
• Caverject injectable and transurethral Consumer Information (Cerner Multum)
• Caverject Advanced Consumer Information (Micromedex)
• Alprostadil Consumer Information (Wolters Kluwer)
• Alprostadil Suppository Consumer Information (Wolters Kluwer)
• Alprostadil injectable and transurethral Consumer Information (Cerner Multum)
• Muse Micro Advanced Consumer Information (Micromedex)
• Alprostadil Intraurethral, Intravenous, Intracavernosal Advanced Consumer Information (Micromedex)
• Alprostadil AHFS DI Monographs (ASHP)